HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Are there treatments for atypical parkinsonism? An update on actual options.

Abstract
Success in treating patients with atypical parkinsonism remains exceedingly low. It is particularly important for both neurologists and general practicians to have a guideline in the actual possible cure options. This study reviews the limited available literature reporting treatment trials about treatment in parkinsonism. Various therapeutical approaches have been tried with rasagiline, immunoglobulin, autologous mesenchymal stem cells, davunetide, lithium, and tideglusib. Recently, the transdermal rotigotine has been proposed for the treatment of atypical parkinsonism, as well as deep brain stimulation (DBS) of the peduncolopontine nucleus alone or combined with globus pallidus internus stimulation. The outcomes reviewed here highlight the need for the development of randomized, placebo-controlled trials to validate outcomes about rotigotine, DBS, and all other new therapies directed at altering the underlying biological mechanisms involved in the disease process.
AuthorsDavide V Moretti
JournalReviews in the neurosciences (Rev Neurosci) Vol. 26 Issue 5 Pg. 547-53 ( 2015) ISSN: 2191-0200 [Electronic] Germany
PMID26098698 (Publication Type: Journal Article, Review)
Chemical References
  • Antiparkinson Agents
Topics
  • Antiparkinson Agents (therapeutic use)
  • Deep Brain Stimulation (methods)
  • Humans
  • Mesenchymal Stem Cell Transplantation (methods)
  • Parkinsonian Disorders (therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: